Trial Profile
A Phase 1b Study of OMP-305B83 Plus FOLFIRI or FOLFOX as Second Line Therapy in Subjects With Metastatic Colorectal Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 28 Feb 2023
Price :
$35
*
At a glance
- Drugs Navicixizumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors OncoMed Pharmaceuticals
- 21 Jan 2023 Results presented at the 2023 Gastrointestinal Cancers Symposium.
- 11 Mar 2019 Status changed from active, no longer recruiting to discontinued.
- 06 Dec 2018 Status changed from recruiting to active, no longer recruiting.